How Reliable Is Ki-67 Immunohistochemistry in Grade 2 Breast Carcinomas? A QA Study of the Swiss Working Group of Breast- and Gynecopathologists-Reference-Cited by-同舟云学术

How Reliable Is Ki-67 Immunohistochemistry in Grade 2 Breast Carcinomas? A QA Study of the Swiss Working Group of Breast- and Gynecopathologists

Published:2012-05-25 Issue:5 Volume:7 Page:e37379
ISSN:1932-6203
Container-title:PLoS ONE
language:en
Short-container-title:PLoS ONE

Author:

Varga Zsuzsanna,Diebold Joachim,Dommann-Scherrer Corina,Frick Harald,Kaup Daniela,Noske Aurelia,Obermann Ellen,Ohlschlegel Christian,Padberg Barbara,Rakozy Christiane,Sancho Oliver Sara,Schobinger-Clement Sylviane,Schreiber-Facklam Heide,Singer Gad,Tapia Coya,Wagner Urs,Mastropasqua Mauro G.,Viale Giuseppe,Lehr Hans-Anton

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference37 articles.

1. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.;M Clarke;Lancet,2005

2. Effect of screening and adjuvant therapy on mortality from breast cancer.;DA Berry;N Engl J Med,2005

3. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007.;A Goldhirsch;Ann Oncol,2007

4. Side effects of adjuvant treatment of breast cancer.;CL Shapiro;N Engl J Med,2001

5. Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients.;E de Azambuja;Br J Cancer,2007

Cited by 175 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Intratumoral heterogeneity of Ki67 proliferation index outperforms conventional immunohistochemistry prognostic factors in estrogen receptor-positive HER2-negative breast cancer;Virchows Archiv;2024-01-13

2. The Japanese breast cancer society clinical practice guidelines for pathological diagnosis of breast cancer, 2022 edition;Breast Cancer;2023-11-07

3. “Diagnostic and Prognostic Biomarkers of Luminal Breast Cancer: Where are We Now?”;Breast Cancer: Targets and Therapy;2023-07

4. Machine Learning Approach for the Determination of the Best Cut-Off Points for Ki67 Proliferation Index in Adjuvant and Neo-Adjuvant Therapy Breast Cancer Patients;Clinical Breast Cancer;2023-07

5. Ki67 in Breast Cancer Assay: An Ad Hoc Testing Recommendation from the Canadian Association of Pathologists Task Force;Current Oncology;2023-03-06